Biochemical predictors of preterm labor: Fetal fibronectin and salivary estriol

Clinics in Perinatology

Volumn 30, Issue 4, 2003, Pages 701-733

  Ramsey, Patrick S ^a   Andrews, William W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BIOLOGICAL MARKER; ERYTHROMYCIN; ESTRIOL; FIBRONECTIN; METRONIDAZOLE;

CLINICAL TRIAL; CONGENITAL MALFORMATION; DRUG EFFICACY; HUMAN; INTRAUTERINE INFECTION; NEWBORN MORBIDITY; NEWBORN MORTALITY; PATHOPHYSIOLOGY; PREDICTION; PREGNANCY; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SALIVA LEVEL; SIDE EFFECT; UNITED STATES; UTERINE CERVIX; VAGINITIS;

EID: 0742321943     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-5108(03)00109-X     Document Type: Review

References (130)

1. Management of preterm labor. ACOG Practice Bulletin No. 43. Obstet Gynecol. 101:2003;1039-1047.
2. Goldenberg R.L., Rouse D.J. Prevention of premature birth. N Engl J Med. 339:1998;313-320.
3. Ramsey P.S., Goldenberg R.L. Obstetric management of prematurity. Fanaroff A.A., Martin R.J. Neonatal-perinatal medicine. 7th edition: 2001;287-319 Mosby Inc, St. Louis, MO. [chapter 16].
4. Goldenberg R.L. The management of preterm labor. Obstet Gynecol. 100:2002;1020-1037.
5. Martin J.A., Hamilton B.E., Ventura S.J., Menacker F., Park M.M., Sutton P.D. Births: final data for 2001. Natl Vital Stat Rep. 51:2002;1-102.
6. Creasy R.K. Preterm birth prevention: Where are we? Am J Obstet Gynecol. 168:1993;1223-1230.
7. McCormick M.C. The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med. 312:1985;82-90.
8. Goldenberg R.L., Iams J.D., Mercer B.M., Meis P.J., Moawad A.H., Copper R.L.et al. The prematurity prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. Am J Public Health. 88:1998;233-238.
9. Iams J.D. Prediction and early detection of preterm labor. Obstet Gynecol. 101:2003;402-412.
10. Tucker J.M., Goldenberg R.L., Davis R.O., Copper R.L., Winkler C.L., Hauth J.C. Etiologies of preterm birth in an indigent population: Is prevention a logical expectation? Obstet Gynecol. 77:1991;343-347.
11. Ascarelli M.H., Morrison J.C. Use of fetal fibronectin in clinical practice. Obstet Gynecol Surv. 52:1997;S1-S12.
12. Andersen H.F. Use of fetal fibronectin in women at risk for preterm delivery. Clin Obstet Gynecol. 43:2000;746-758.
13. Mauldin J.G., Newman R.B. Preterm birth risk assessment. Sem Perinatol. 25:2001;215-222.
14. Lockwood C.J., Senyei A.E., Dische M.R., Casal D., Shah K.D., Thung S.N.et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med. 325:1991;669-674.
15. Lockwood C.J., Wein R., Lapinski R., Casal D., Berkowitz G., Alvarez M. et al. The presence of cervical and vaginal fetal fibronectin predicts preterm delivery in an inner-city obstetric population. Am J Obstet Gynecol. 169:1993;798-804.
16. Feinberg R.F., Kliman H.J., Lockwood C.J. Is oncofetal fibronectin a trophoblast glue for human implantation? Am J Pathol. 138:1991;537-543.
17. Leeson S., Maresh M. Fibronectin: a predictor of preterm delivery? Br J Obstet Gynaecol. 100:1993;304-306.
18. Leitich H., Egarter C., Kaider A., Hohlagschwandtner M., Berghammer P., Hussein P. Cervicovaginal fetal fibronectin as a marker for preterm delivery: a meta-analysis. Am J Obstet Gynecol. 180:1999;1169-1176.
19. Faron G., Boulvain M., Irion O., Bernard P.M., Fraser W.D. Prediction of preterm delivery by fetal fibronectin: a meta-analysis. Obstet Gynecol. 92:1998;153-158.
20. Revah A., Hannah M.E., Sue-A-Quan A.K. Fetal fibronectin as a predictor of preterm birth: an overview. Am J Perinatol. 15:1998;613-621.
21. Goldenberg R.L., Mercer B.M., Meis P.J., Copper R.L., Das A., McNellis D. The Preterm Prediction Study: fetal fibronectin testing and spontaneous preterm birth. Obstet Gynecol. 87:1996;643-648.
22. Peaceman A.M., Andrews W.W., Thorp J.M., Cliver S.P., Lukes A., Iams J.D.et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol. 177:1997;13-18.
23. Honest H., Bachmann L.M., Gupta J.K., Kleijnen J., Khan K.S. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ. 325:2002;1-10.
24. Bittar R.E., Yamasaki A.A., Sasaki S., Zugaib M. Cervical fetal fibronectin in patients at increased risk for preterm delivery. Am J Obstet Gynecol. 175:1996;178-181.
25. Chang T.C., Chew T.S., Pang M., Tan A.C., Yeo G.S. Cervicovaginal foetal fibronectin in the prediction of preterm labour in a low-risk population. Ann Acad Med Singapore. 26:1997;776-780.
26. Bartnicki J., Casal D., Kreaden U.S., Saling E., Vetter K. Fetal fibronectin in vaginal specimens predicts preterm delivery and very-low-birth-weight infants. Am J Obstet Gynecol. 174:1996;971-974.
27. LaShay N., Gilson G., Joffe G., Qualls C., Curet L. Will cervicovaginal interleukin-6 combined with fetal fibronectin testing improve the prediction of preterm delivery? J Matern Fetal Med. 9:2000;336-341.
28. Rizzo G., Capponi A., Arduini D., Lorido C., Romanini C. The value of fetal fibronectin in cervical and vaginal secretions and of ultrasonographic examination of the uterine cervix in predicting premature delivery for patients with preterm labor and intact membranes. Am J Obstet Gynecol. 175:1996;1146-1151.
29. Rizzo G., Capponi A., Vlachopoulou A., Angelini E., Grassi C., Romanini C. The diagnostic value of interleukin-8 and fetal fibronectin concentrations in cervical secretions in patients with preterm labor and intact membranes. J Perinat Med. 25:1997;461-468.
30. Iams J.D., Casal D., McGregor J.A., Goodwin T.M., Kreaden U.S., Lowensohn R.et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol. 173:1995;141-145.
31. Leeson S.C., Maresh M.J.A., Martindale E.A., Mahmood T., Muotune A., Hawkes N.et al. Detection of fetal fibronectin as a predictor of preterm delivery in high risk asymptomatic pregnancies. Br J Obstet Gynaecol. 103:1996;48-53.
32. Tolino A., Ronsini S., Zullo F., Pellicano M., Regine V., Nappi C. Fetal fibronectin as a screening test for premature delivery in multiple pregnancies. Int J Gynaecol Obstet. 52:1996;3-7.
33. Faron G., Boulvain M., Lescrainier J.P., Vokaer A. A single cervical fetal fibronectin screening test in a population at low risk for preterm delivery: an improvement on clinical indicators? Br J Obstet Gynaecol. 104:1997;697-701.
34. Hellemans P., Gerris J., Verdonk P. Fetal fibronectin detection for prediction of preterm birth in low risk women. Br J Obstet Gynaecol. 102:1995;207-212.
35. Crane J.M., Armson B.A., Dodds L., Feinberg R.F., Kennedy W., Kirkland S.A. Risk scoring, fetal fibronectin, and bacterial vaginosis to predict preterm delivery. Obstet Gynecol. 93:1999;517-522.
36. Garcia-Alonso A., Ayala-Mendez J.A., Izquierdo-Puente J.C., Jiménez-Solis G., Sánchez-Martinez M. Presencia de fibronectina fetal en secrecion cervico-vaginal como predictor de parto pretermino. Ginecol Obstet Mex. 67:1999;23-28.
37. Greenhagen J.B., Van Wagoner J., Dudley D., Hunter C., Mitchell M., Logsdon V.et al. Value of fetal fibronectin as a predictor of preterm delivery for a low-risk population. Am J Obstet Gynecol. 175:1996;1054-1056.
38. DiStefano L., Carta G., Di Paolantonio L., Palerno P., Moscarini M. Preterm delivery: predictive value of cervico-vaginal fetal fibronectin. Clin Exp Obstet Gynecol. 26:1999;187-189.
39. Zamora-Scorza F.C., Fernandez G., de Lamanna M.P., Perez M.C., Maris C.A. Valor de la fibronectina fetal en secreciones cervicales en la prediccion del parto pretermino en pacientes con membranas integras. Rev Obstet Ginecol Venez. 60:2000;15-22.
40. Roubille M., Mailliavin A., Biguet-Vernier B., Bon C., Golfier F., Pichot J.C. Interet de la recherche de la fibronectine foetale dans le depitage du risque d'accouchement premature. Ann Biol Clin (Paris). 57:1999;93-97.
41. Nageotte M.P., Casal D., Senyei A.E. Fetal fibronectin in patients at increased risk for premature birth. Am J Obstet Gynecol. 170:1994;20-25.
42. Oliveira T.A., Carvalho C.M., de Souza E., Mariani-Neto C., Camano L. Detection of fetal fibronectin in twin pregnancies in relation to gestational age. Sao Paulo Med J. 117:1999;121-124.
43. Krems J., McGregor J., Hastings C., Hanson J. Fetal fibronectin in cervical secretions: an aid for predicting delivery in women at high risk for preterm delivery. Am J Obstet Gynecol. 172:1995;406.
44. Goldenberg R.L., Klebanoff M., Carey J.C., MacPherson C., Leveno K.J., Moawad A.H.et al. Vaginal fetal fibronectin measurements from 8 to 22 weeks' gestation and subsequent spontaneous preterm birth. Am J Obstet Gynecol. 183:2000;469-475.
45. Goldenberg R.L., Mercer B.M., Iams J.D., Moawad A.H., Meis P.J., Das A. et al. The preterm prediction study: patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery. Am J Obstet Gynecol. 177:1997;8-12.
46. Goldenberg R.L., Mercer B.M., Meis P.J., Copper R.L., Das A., McNellis D. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth. Obstet Gynecol. 87:1996;643-648.
47. Wennerholm U.B., Holm B., Mattsby-Baltzer I., Nielsen T., Platz-Christensen J., Sundell G.et al. Fetal fibronectin, endotoxin, bacterial vaginosis and cervical length as predictors of preterm birth and neonatal morbidity in twin pregnancies. Br J Obstet Gynaecol. 104:1997;1398-1404.
48. Hux C.H., Trolice M.P., Kadar N. The value of a single fetal fibronectin assay as a screen for preterm labor and delivery. J Matern Fetal Med. 4:1995;100-104.
49. Inglis S.R., Jeremias J., Kuno K., Lescale K., Peeper Q., Chervenak F.A.et al. Detection of tumor necrosis factor-alpha, interleukin-6, and fetal fibronectin in the lower genital tract during pregnancy: relation to outcome. Am J Obstet Gynecol. 171:1994;5-10.
50. Vercoustre L., Sotter S., Bouige D., Walch R. Fibronectin as a predictor of labor, results and discussion about 206 samples. Gynecol Obstet. 4:1996;23-32.
51. Malagrida L., Rozenberg P., Simon G., Giudicelli Y. Detection of fetal fibronectin in cervical and secretions to predict preterm birth. Immuno Anal Biol Spec. 10:1995;355-359.
52. Calda P., Cibula D., Doudova D., Binder T., Peterka T., Zizka Z.et al. Fetal fibronectin in cervico-vaginal secretions-an indicator of incipient premature labor using a membrane immunoassay. Ceska Gynekol. 60:1995;293-295.
53. Surbek D., Bosiger H., Pavic N., Huber P., Almendral A.C., Holzgreve W. Fetal fibronectin as a predictor of preterm birth in patients at increased risk. Z Geburtshilfe Neonatol. 201:1997;15-20.
54. Goffeng A.R., Holst E., Milsom I., Lindstedt G., Lundberg P.A., Andersch B. Fetal fibronectin and microorganisms in vaginal fluid of women with complicated pregnancies. Acta Obstet Gynecol Scand. 76:1997;521-527.
55. Irion O., Matute J., Bischof P. Prediction of prematurity with oncofoetal fibronectin: prospective cohort study. J Gynecol Obstet Biol Reprod (Paris). 24:1995;624-629.
56. Langer B., Boudier E., Schlaeder G. Cervico-vaginal fetal fibronectin: predictive value during false labor. Acta Obstet Gynecol Scand. 76:1997;218-221.
57. Lopez R.L., Francis J.A., Garite T.J., Dubyak J.M. Fetal fibronectin detection as a predictor of preterm birth in actual clinical practice. Am J Obstet Gynecol. 182:2000;1103-1106.
58. Malak T.M., Sizmur F., Bell S.C., Taylor D.J. Fetal fibronectin in cervicovaginal secretions as a predictor of preterm birth. Br J Obstet Gynaecol. 103:1996;648-653.
59. Rozenberg P., Goffinet F., Malagrida L., Giudicelli Y., Perdu M., Houssin I.et al. Evaluating the risk of preterm delivery: a comparison of fetal fibronectin and transvaginal ultrasonographic measurement of cervical length. Am J Obstet Gynecol. 176:1997;196-199.
60. Mansouri A., Tadjerouni A., El Rabiey G., Baube S., Garnier G., Tribalat S. Is fetal fibronectin a valid test predictive of preterm delivery? Contracept Fertil Sex. 25:1997;380-384.
61. Vetr M., Kudela M., Prasilova J. Fetal fibronectin in patients at increased risk for premature birth. Acta Univ Palacki Olomuc Fac Med. 140:1996;55-57.
62. Chuileannain F.N., Bell R., Brennecke S. Cervicovaginal fetal fibronectin testing in threatened preterm labour-translating research findings into clinical practice. Aust N Z J Obstet Gynaecol. 38:1998;399-402.
63. Cox S., Little B., Dax J., Leveno K. Fetal fibronectin and preterm delivery. Am J Obstet Gynecol. 174:1996;306.
64. Giles W., Bisits A., Knox M., Madsen G., Smith R. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am J Obstet Gynecol. 182:2000;439-442.
65. Benattar C., Taieb J., Fernandez H., Lindendaum A., Frydman R., Ville Y. Rapid fetal fibronectin swab-test in preterm labor patients treated by betamimetics. Eur J Obstet Gynecol Reprod Biol. 72:1997;131-135.
66. Grandi C., Perego M., Briozzo G., Cassini A. Fibronectina fetal (fFN) en secrecion cervical como predictor del parto prematuro. Rev Hosp Mat Inf Ramon Sarda. 15:1996;127-136.
67. Morrison J.C., Allbert J.R., McLaughlin B.N., Whitworth N.S., Roberts W.E., Martin R.W. Oncofetal fibronectin in patients with false labor as a predictor of preterm delivery. Am J Obstet Gynecol. 168:1993;538-542.
68. Nageotte M.P., Hollenbach K.A., Vanderwahl B.A., Hutch K.M. Oncofetal fibronectin in patients at increased risk for preterm delivery. Am J Obstet Gynecol. 166:1992;274.
69. Hampl M., Friese K., Hofmann I., Melchert F. Quantitative determination of fetal fibronectin in cervical smears: a new marker for evaluating the risk in premature labour. Geburtshilfe Frauenheilkd. 54:1994;685-690.
70. Goldenberg R.L., Hauth J.C., Andrews W.W. Intrauterine Infection and preterm delivery. N Engl J Med. 342:2000;1500-1507.
71. Hauth J.C., Andrews W.W., Goldenberg R.L. Infection-related risk factors predictive of spontaneous preterm labor and birth. Prenat Neonat Med. 3:1998;86.
72. Andrews W.W., Hauth J.C., Goldenberg R.L., Gomez R., Romero R., Cassell G.H. Amniotic fluid interleukin-6: Correlation with upper genital tract microbial colonization and gestational age in women delivered after spontaneous labor versus indicated delivery. Am J Obstet Gynecol. 173:1995;606-612.
73. Hillier S.L., Martius J., Krohn M., Kiviat N., Holmes K.K., Eschenbach D.A. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med. 319:1998;972-978.
74. Watts D.H., Krohn M.A., Hillier S.L., Eschenbach D.A. The association of occult amniotic fluid infection with gestational age and neonatal outcome among women in preterm labor. Obstet Gynecol. 79:1992;351-357.
75. Goldenberg R.L., Iams J.D., Mercer B.M., Meis P.J., Moawad A., Das A.et al. The Preterm Prediction Study: Toward a multiple-marker test for spontaneous preterm birth. Am J Obstet Gynecol. 185:2001;643-651.
76. Goldenberg R.L., Thom E., Moawad A.H., Johnson F., Roberts J., Caritis S.N. The preterm prediction study: fetal fibronectin, bacterial vaginosis, and peripartum infection. NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol. 87:1996;656-660.
77. Goepfert A.R., Goldenberg R.L., Mercer B., Iams J., Meis P., Moawad A.et al. The preterm prediction study: Quantitative fetal fibronectin values and the prediction of spontaneous preterm birth. Am J Obstet Gynecol. 183:2000;1480-1483.
78. McKenna D.S., Chung K., Iams J.D. Effect of digital cervical examination on the expression of fetal fibronectin. J Reprod Med. 44:1999;796-800.
79. Shimoya K., Hashimoto K., Shimizu T., Saji F., Murata Y. Effect of sexual intercourse on fetal fibronectin concentration in cervicovaginal secretions. Am J Obstet Gynecol. 179:1998;255-256.
80. Feinberg R.F., Wang C.L. Monoclonal antibody FDC-6 exhibits binding to human plasma fibronectin: A caveat for cervicovaginal oncofetal fibronectin testing? Am J Obstet Gynecol. 171:1994;1302-1308.
81. Eriksen N.L., Parisi V.M., Daoust S., Flamm B., Garite T.J., Cox S.M. Fetal fibronectin: a method of detecting the presence of amniotic fluid. Obstet Gynecol. 80:1992;451-454.
82. Beckmann M.W., Wiegratz I., Dereser M.M., Baier P., Born H.J. Diagnosis of rupture of fetal membranes: comparison of vaginal detection of fetal fibronectin and intra-amnion injection of indigo carmine. Geburtshilfe Frauenheilkd. 53:1993;86-91.
83. Lukes A.S., Thorp J.M. Jr., Eucker B., Pahel-Short L. Predictors of positivity for fetal fibronectin in patients with symptoms of preterm labor. Am J Obstet Gynecol. 176:1997;639-641.
84. Goffeng A.R., Holst E., Milsom I., Lindstedt G., Lundberg P.A., Andersch B. Fetal fibronectin and microorganisms in vaginal fluid of women with complicated pregnancies. Acta Obstet Gynecol Scand. 76:1997;521-527.
85. Goffeng A.R., Holst E., Milsom I., Lindstedt G., Lundberg P.A., Andersch B. Fetal fibronectin and microorganisms in vaginal fluid of healthy pregnant women. Acta Obstet Gynecol Scand. 75:1996;520-525.
86. Joffe G.M., Jacques D., Bemis-Heys R., Burton R., Skram B., Shelburne P. Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol. 180:1999;581-586.
87. Sullivan A., Hueppchen N.A., Satin A.J. Cost effectiveness of bedside fetal fibronectin testing varies according to treatment algorithm. J Matern Fetal Med. 10:2001;380-384.
88. Mozurkewich E.L., Naglie G., Krahn M.D. Predicting preterm birth: A cost-effectiveness analysis. Am J Obstet Gynecol. 182:2000;1589-1598.
89. Grobman W., Welshman E., Calhoun E. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs. Am J Obstet Gynecol. 187:2003;S80.
90. Ramsey P.S., Repke J.T. Intrapartum management of multifetal pregnancies. Semin Perinatol. 27:2003;54-72.
91. Goldenberg R.L., Iams J.D., Miodovnik M., Van Dorsten J.P., Thurnau G., Bottoms S.et al. The preterm prediction study: Risk factors in twin gestations. Am J Obstet Gynecol. 175:1996;1047-1053.
92. Oliveira T., De Souza E., Mariani-Neto C., Camano L. Fetal fibronectin as a predictor of preterm delivery in twin gestations. Int J Gynecol Obstet. 62:1998;135-139.
93. Terrone D.A., Rinehart B.K., Kraeden U., Morrison J.C. Fetal fibronectin in symptomatic twin gestations. Prim Care Update Ob Gyn. 5:1998;179.
94. Roberts W.E., Morrison J.C. Has the use of home monitors, fetal fibronectin, and measurement of cervical length helped predict labor and/or prevent preterm delivery in twins? Clin Obstet Gynecol. 41:1998;94-102.
95. Gibbs R.S., Romero R., Hillier S.L., Eschenbach D.A., Sweet R.L. A review of premature birth and subclinical infection. Am J Obstet Gynecol. 166:1992;1515-1528.
96. King J., Flenady V. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database Syst Rev. (4):2002;CD000246.
97. Goldenberg R.L., Klebanoff M., Carey J.C., MacPherson C. Metronidazole treatment of women with a positive fetal fibronectin test result. Am J Obstet Gynecol. 185:2001;485-486.
98. Carey J.C., Klebanoff M.A., Hauth J.C., Hillier S.L., Thom E.A., Ernest J.M.et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med. 342:2000;534-540.
99. Hauth J.C., Cliver S., Hodgkins P., Andrews W.W., Schwebke J.R., Hook E.W.et al. Mid-trimester metronidazole and azithromycin did not prevent preterm birth in women at increased risk: A double-blinded trial. Am J Obstet Gynecol. 185:2001;S86.
100. Crenshaw S., Briley A., Hawken J., Chinn S., Judah J., Jones G.et al. Double blind placebo controlled trial (PREMET) of metronidazole to prevent early preterm delivery in high risk, fetal fibronectin positive women. J Soc Gynecol Investig. 10:2003;323A.
101. Andrews W.W., Sibai B.M., Thom E.A., Dudley D., Ernest J.M., McNellis D.et al. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. Obstet Gynecol. 101:2003;847-855.
102. Hauth J.C., Goldenberg R.L., Andrews W.W., DuBard M.B., Cooper R.L. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 333:1995;1732-1736.
103. Klebanoff M.A., Carey J.C., Hauth J.C., Hillier S.L., Nugent R.P., Thom E.A.et al. Failure of metronidazole to prevent preterm birth among asymptomatic women with Trichomonas vaginalis. N Engl J Med. 345:2001;487-493.
104. Bashore R.A., Westlake J.R. Plasma unconjugated estriol values in high risk pregnancy. Am J Obstet Gynecol. 128:1997;371-380.
105. Beischer N., Brown J., Parkinson P., Walstab J. Urinary oestriol assay for monitoring fetoplacental functio. Aust N Z J Obstet Gynaecol. 31:1991;1-8.
106. Beischer N., Brown J., Wein P., Sheedy M., Stereff M., Boras M. The biochemistry and clinical application of urinary oestriol measurement during late pregnancy in the 1990s. Aust NZ Obstet Gynaecol. 35:1995;151-159.
107. Hagerman D.D. Clinical use of plasma total estriol measurements in late pregnancy. J Repro Med. 23:1979;179-184.
108. Dooley S.L., Depp R., Socol M.L., Tamura R.K., Vaisrub N. Urinary estriols in diabetic pregnancy: a reappraisal. Obstet Gynecol. 64:1984;469-475.
109. Duenhoelter J.H., Whalley P.J., MacDonald P.C. An analysis of the utility of plasma immunoreactive estrogen measurements in determining delivery time of gravidas with a fetus considered at high risk. Am J Obstet Gynecol. 125:1976;889-898.
110. Schneider J.M., Olson R.W., Curet L.B. Screening for fetal and neonatal risk in the postdate pregnancy. Am J Obstet Gynecol. 131:1978;473-478.
111. Jackson M., Dudley D.J. Endocrine assays to predict preterm delivery. Clin Perinatol. 25:1998;837-857.
112. Goodwin T.M. A role for estriol in human labor, term and preterm. Am J Obstet Gynecol. 180:1999;S208-S213.
113. Hedriana H.L., Munro C.J., Eby-Wilkens E.M., Lasley B.L. Changes in rates of salivary estriol increases before parturition at term. Am J Obstet Gynecol. 184:2001;123-130.
114. Lachelin G.C., McGarrigle H.H. A comparison of saliva, plasma unconjugated and plasma total oestriol levels throughout normal pregnancy. Br J Obstet Gynaecol. 91:1984;1203-1209.
115. Darne J., McGarrigle H.H., Lachelin G.C. Saliva oestriol, oestradiol, oestrone and progesterone levels in pregnancy: spontaneous labour at term is preceded by a rise in salivary oestriol: progesterone ratio. Br J Obstet Gynaecol. 94:1987;227-235.
116. McGarrigle H.H., Lachelin G.C. Increasing saliva (free) oestriol to progesterone ratio in late pregnancy: a role for oestriol in initiating spontaneous labour in man? BMJ. 289:1984;457-459.
117. Moran D.J., McGarrigle H.H., Lachelin G.C. Lack of normal increase in saliva estriol/progesterone ratio in women with labor induced at 42 weeks' gestation. Am J Obstet Gynecol. 167:1992;1563-1564.
118. Voss H.F. Saliva as a fluid for measurement of estriol levels. Am J Obstet Gynecol. 180:1999;226-231.
119. Vining R.F., McGinley R., Rice B.V. Saliva estriol measurements: an alternative to the assay of serum unconjugated estriol assessing feto-placental function. J Clin Endocrinol Metab. 56:1983;454-460.
120. Evans J.J., Wilkinson A.R., Aickin D.R. Salivary estriol concentrations during normal pregnancies, and a comparison with plasma estriol. Clin Chem. 30:1984;120-121.
121. Cusick P.E., Alston W.C., Truran P.L., Read G.F. Sub-hourly variations in salivary estriol concentrations in the last trimester of pregnancy. Acta Obstet Gynecol Scand. 65:1986;435-448.
122. McGregor J.A., Hastings C., Roberts T., Barrett J. Diurnal variation in saliva estriol during pregnancy: a pilot study. Am J Obstet Gynecol. 180:1999;S223-S225.
123. Hendershott C.M., Dullien V., Goodwin T.M. Serial betamethasone administration and effect on maternal salivary estriol levels. J Soc Gynecol Invest. 3:1996;276A.
124. Leff R.P., Goldkrand J.W. The effect of betamethasone on salivary estriol. J Matern Fetal Neonatal Med. 11:2002;192-195.
125. Hull M.G., Monro P.P., Gillmer M.D. Plasma unconjugated oestriol in late pregnancy: circadian variation and the effect of meals and a glucose load. Br J Obstet Gynaecol. 85:1978;645-651.
126. Heine R.P., McGregor J.A., Goodwin T.M., Artal R., Hayashi R.H., Robertson P.A.et al. Serial salivary estriol to detect an increased risk of preterm birth. Obstet Gynecol. 96:2000;490-497.
127. Heine R.P., McGregor J.A., Dullien V.K. Accuracy of salivary estriol testing compared to traditional risk factor assessment in predicting preterm birth. Am J Obstet Gynecol. 180:1999;S214-S218.
128. McGregor J.A., Jackson G.M., Lachelin G.C., Goodwin T.M., Artal R., Hastings C.et al. Salivary estriol as risk assessment for preterm labor: a prospective trial. Am J Obstet Gynecol. 173:1995;1337-1342.
129. Creasy R.K.et al. System for predicting spontaneous preterm birth. Obstet Gynecol. 55:1980;692.
130. Darne J., McGarrigle H.H.G., Lachelin G.C. Increased saliva oestriol to progesterone ration before idiopathic preterm delivery: a possible predictor for preterm labour? BMJ. 294:1987;270-272.